BRCA2 mutation carriers diagnosed with cancer may respond differently to certain treatments. For example, PARP inhibitors have shown effectiveness in treating cancers associated with BRCA mutations. These drugs target cancer cells' ability to repair DNA, making them particularly suited for BRCA-related cancers.